RNA-Targeting CRISPR-Cas systems and their applications
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)–CRISPR-associated (Cas) systems have revolutionized modern molecular biology. Numerous types of these systems have been discovered to date. Many CRISPR–Cas systems have been used as a backbone for the development of potent research tools, with Cas9 being the most widespread. While most of the utilized systems are DNA-targeting, recently more and more attention is being gained by those that target RNA. Their ability to specifically recognize a given RNA sequence in an easily programmable way makes them ideal candidates for developing new research tools. In this review we summarize current knowledge on CRISPR–Cas systems which have been shown to target RNA molecules, that is type III (Csm/Cmr), type VI (Cas13), and type II (Cas9). We also present a list of available technologies based on these systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cas clusters described in PCC 9108 mainly belong to type III CRISPR -Cas systems, the most diverse and complex CRISPR, able to cleave RNA and DNA, and the only known that use three nuclease ac tivities (Burmistrz et al., 2020; Molina et al., 2020) (Table 1).”
From Characterization of Limnospira platensis PCC 9108 R-M and CRISPR-Cas systems (2024) · cites this paper as Burmistrz et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 3×
“The strand containing complementary to crRNA and the displaced strand are cleaved by HNH and RuvC domains, respectively [9,56].”
BackgroundMethodCRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 1×
“During the adaptation phase, new spacers are incorporated into the CRISPR array into its leader end [6].”
BackgroundNucleic acid detection with CRISPR-Cas13a/C2c2
Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., Verdine, V., Donghia, N., Daringer, N. M., Freije, C. A., et al. (2017) · Science · doi:10.1126/science.aam9321 · Cited by 3,844 · cited 9×
“An example for that is its utilization as a backbone for in vitro detection method of DNA and RNA named Specific High-Sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) [67].”
BackgroundMethodInfluentialMultiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J., & Zhang, F. (2018) · Science · doi:10.1126/science.aaq0179 · Cited by 2,638 · cited 5×
“The potential clinical applications of RNA-targeting CRISPR–Cas systems include but are not limited to: rapid detection of various nucleic acids [67,68], treatment of diseases related to G to A mutations using RNA editing [66], treatment of genetic diseases using RNA knockdown, treatment of diseases related to incorre…”
BackgroundMethodInfluentialCRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563 · cited 2×
“The 5′ fragment of tracrRNA binds to a repeat sequence, creating a duplex which is cleaved by RNase III [8].”
BackgroundC2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B. T., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., et al. (2016) · Science · doi:10.1126/science.aaf5573 · Cited by 2,336 · cited 6×
“To date, four subtypes have been distinguished: VI-A (that uses Cas13a variant, alternatively known as C2c2), VI-B (Cas13b/C2c6), VI-C (Cas13c/C2c7), and VI-D (Cas13d) [47,48].”
BackgroundInfluentialRNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093 · cited 6×
“To date, four subtypes have been distinguished: VI-A (that uses Cas13a variant, alternatively known as C2c2), VI-B (Cas13b/C2c6), VI-C (Cas13c/C2c7), and VI-D (Cas13d) [47,48].”
BackgroundInfluentialCRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats
Grissa, I., Vergnaud, G., & Pourcel, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm360 · Cited by 1,875 · cited 1×
“CRISPR–Cas systems are very common in the prokaryotic world, as they are detected in around half of the bacterial and archeal species known to date [17,21].”
BackgroundCox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017) · Science · doi:10.1126/science.aaq0180 · Cited by 1,834 · cited 7×
“RNA editing Cas13b (REPAIR) dCas13b is fused to ADAR2 domain enables to convert selected adenosine to inosine small size enables delivery via AAV [66]”
BackgroundMethodInfluentialIdentification of genes that are associated with DNA repeats in prokaryotes
Jansen, R., Embden, J. D. A. V., Gaastra, W., & Schouls, L. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02839.x · Cited by 1,802 · cited 1×
“Together with the leader sequence these spacers and repeats constitute the CRISRP array [4,5].”
Background
Cited by
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2
Atzrodt, C. L., Maknojia, I., McCarthy, R. D. P., Oldfield, T. M., Po, J., Ta, K. T. L., Stepp, H. E., & Clements, T. P. (2020) · The FEBS Journal · doi:10.1111/febs.15375 · Cited by 341
CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance
Mayorga-Ramos, A., Zúñiga-Miranda, J., Carrera-Pacheco, S. E., Barba-Ostria, C., & Guamán, L. P. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00649 · Cited by 207
Gene therapy for ALS: A review
Amado, D. A., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.008 · Cited by 184
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 171
“For example, a protospacer flanking sequence is recognized by Type VI systems, which use Cas13 to cleave RNA [9].”
BackgroundApplication of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction
Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M. H., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020152 · Cited by 99
“2008 CRISPR acts upon DNA target [42,43] Discovered the function of crRNA”
BackgroundExosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants
Alghuthaymi, M. A., Ahmad, A., Khan, Z., Khan, S. H., Ahmed, F. K., Faiz, S., Nepovimova, E., Kuča, K., & Abd-Elsalam, K. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147456 · Cited by 83
“Cas13 is an RNA-guided endonuclease, which implies that it does not cut DNA but rather single-stranded RNA [24].”
BackgroundApplications of CRISPR/Cas13-Based RNA Editing in Plants
Kavuri, N. R., Ramasamy, M., Qi, Y., & Mandadi, K. K. (2022) · Cells · doi:10.3390/cells11172665 · Cited by 87
Classification of CRISPR/Cas system and its application in tomato breeding
Chaudhuri, A., Halder, K., & Datta, A. (2022) · Theoretical and Applied Genetics · doi:10.1007/s00122-021-03984-y · Cited by 85
CRISPR-induced DNA reorganization for multiplexed nucleic acid detection
Karlikow, M., Amalfitano, E., Yang, X., Doucet, J., Chapman, A., Mousavi, P. S., Homme, P., Sutyrina, P., Chan, W., Lemak, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36874-6 · Cited by 77
Cas13d: A New Molecular Scissor for Transcriptome Engineering
Gupta, R. K., Ghosh, A., Chakravarti, R., Singh, R., Ravichandiran, V., Swarnakar, S., & Ghosh, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.866800 · Cited by 81
“On the other hand, such “collateral cleavage” by Cas13 has not been detected in mammalian cells and even in plants, making it a pro and robust tool for spatiotemporal transcriptional editing and manipulation in the eukaryotic system (O’ Connell, 2019; Burmistrz et al., 2020; Kling, 2020; Zaccara et al., 2019; Palaz et…”
BackgroundHalder, K., Chaudhuri, A., Abdin, M. Z., Majee, M., & Datta, A. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.885128 · Cited by 77
Wang, D., Jin, S., Lu, Q., & Chen, Y. (2023) · Journal of Fungi · doi:10.3390/jof9030362 · Cited by 76
AKT kinases as therapeutic targets
Hassan, D., Menges, C. W., Testa, J. R., & Bellacosa, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03207-4 · Cited by 82
“…anti-sense oligonucleotides (ASOs) (anti-miRNA oligonucleotides, peptide nucleic acids, Locked Nucleic Acid (LNA), morpholinos) [372], ribozymes [373], long non-coding RNAs (LncRNA) [374], and CRISPR [375], which are all designed to bind to target RNA transcripts via complementary base-pairing.”
Progress in gene editing tools, implications and success in plants: a review
Bhuyan, S. J., Kumar, M., Devde, P. R., Rai, A. C., Mishra, A. K., Singh, P. K., & Siddique, K. H. M. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1272678 · Cited by 70
“Type VI CRISPR-Cas systems offer a wide range of applications in diverse organisms through various RNA technologies such asRNA interference, RNA detection, RNA editing, and RNA targeting (Burmistrz et al., 2020; Kordy ś et al., 2022; F. Wang et al., 2019).”
BackgroundFunctional Features and Current Applications of the RNA‐Targeting Type VI CRISPR‐Cas Systems
Perčulija, V., Lin, J., Zhang, B., & Ouyang, S. (2021) · Advanced Science · doi:10.1002/advs.202004685 · Cited by 71
Precision Breeding Made Real with CRISPR: Illustration through Genetic Resistance to Pathogens
Veillet, F., Durand, M., Kroj, T., Césari, S., & Gallois, J. (2020) · Plant Communications · doi:10.1016/j.xplc.2020.100102 · Cited by 62
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
Hasanzadeh, A., Alamdaran, M., Ahmadi, S., Nourizadeh, H., Bagherzadeh, M. A., Jahromi, M. A. M., Simon, P. D., Karimi, M., & Hamblin, M. R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.036 · Cited by 60
“In a recent study, a gene-editing system was developed based on Cas13e.1 (type VI) that could successfully cleave SARS-CoV-2 sequences as well as influenza A virus in cultured HEK293T and N2A cells.”
InfluentialDanilenko, V., Devyatkin, A., Marsova, M., Shibilova, M., Ilyasov, R. A., & Shmyrev, V. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s333887 · Cited by 57
“Chen Y, Gu S, Chen Y, et al. Six-month follow-up of gut microbiota richness in patients with COVID-19.”
BackgroundInfluentialCRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials
Khalaf, K., Janowicz, K., Dyszkiewicz-Konwińska, M., Hutchings, G., Dompé, C., Moncrieff, L., Jankowski, M., Machnik, M., Oleksiewicz, U., Kocherova, I., et al. (2020) · Genes · doi:10.3390/genes11080921 · Cited by 54
“After spacer insertion, CRISPR array associated Cas9 operon facilitates the co-transcription of the entire spacer region resulting in the formation of an immature segment called pre-crRNA, consisting of newly added spacer and host DNA [11].”
BackgroundInfluentialThe Use of Genetic and Gene Technologies in Shaping Modern Rapeseed Cultivars (Brassica napus L.)
Ton, L. B., Neik, T. X., & Batley, J. (2020) · Genes · doi:10.3390/genes11101161 · Cited by 57
“The most commonly applied genome editing tool in eukaryotes in the last 8 years, the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR‐associated protein (Cas) system [37,38], is gaining more interest compared to conventional genetic modification methods due to its high efficiency in targeted nu…”
MethodMechanisms regulating the CRISPR-Cas systems
Zakrzewska, M., & Burmistrz, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1060337 · Cited by 51
“The extensive description of mechanisms of CRISPR-Cas systems biology and mechanisms can be found here (Mohanraju et al., 2016; Burmistrz et al., 2020).”
BackgroundSelf-citationCRISPR Approaches for the Diagnosis of Human Diseases
Puig-Serra, P., Casado-Rosas, M. C., Martínez-Lage, M., Olalla-Sastre, B., Alonso-Yanez, A., Torres-Ruiz, R., & Rodríguez, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031757 · Cited by 50
“HEPN domains must detect the so-called Protospacer Flanking Sequence (PFS) in close proximity to the target protospacer sequence in order for the catalytic site to be activated [65].”
BackgroundCRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics
Lu, J., Liu, J., Guo, Y., Zhang, Y., Xu, Y., & Wang, X. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.007 · Cited by 46
Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family
Liu, L., & Pei, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911400 · Cited by 48
“CRISPR-mediated adaptive immunity consists of three phases: adaptation, maturation, and interference (Figure 1) [21].”
BackgroundPadayachee, J., & Singh, M. (2020) · Nanobiomedicine · doi:10.1177/1849543520983196 · Cited by 44
Durán‐Vinet, B., Araya‐Castro, K., Calderón, J. F., Vergara, L. F., Weber, H. L., Retamales, J., Araya-Castro, P., & Leal, P. (2021) · Cancers · doi:10.3390/cancers13184640 · Cited by 40
Functional annotation of lncRNA in high-throughput screening
Yip, C. W., Sivaraman, D. M., Prabhu, A. V., & Shin, J. W. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200061 · Cited by 42
miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities
Huang, W., Paul, D., Călin, G. A., & Bayraktar, R. (2023) · Cells · doi:10.3390/cells13010084 · Cited by 37
“Recombinant viral vectors can consist of integrating retroviruses and lentiviruses or non-integrating adenoviruses and adeno-associated viruses (AAVs) [307].”
Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment
Souri, M., Chiani, M., Farhangi, A. A., Mehrabi, M. R., Nourouzian, D., Raahemifar, K., & Soltani, M. (2022) · Nanomaterials · doi:10.3390/nano12050783 · Cited by 37
“It is therefore critical to target multiple genomic sites [273,274].”
BackgroundThe Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics
Abril, A. G., Carrera, M., Notario, V., Sánchez-Pérez, Á., & Villa, T. G. (2022) · Antibiotics · doi:10.3390/antibiotics11050653 · Cited by 40
Improving recombinant protein production in CHO cells using the CRISPR-Cas system
Kalkan, A. K., Palaz, F., Semeniuk, S., Elmousa, N., Ledezma, Y., Cachat, É., & Rios‐Solis, L. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108115 · Cited by 38
Sokpor, G., Xie, Y., Nguyen, H. P., & Tuoc, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.656849 · Cited by 35
Mostafa, M., Barhoum, A., Sehit, E., Gewaid, H. E., Mostafa, E., Omran, M. M., Abdalla, M. S., Abdel‐Haleem, F. M., Altıntaş, Z., & Forster, R. J. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116750 · Cited by 32
“30 is relatively simple in design, and its activity requires only one molecule of Cas13 enzyme and one 607 crRNA molecule [144].”
Elimination of blaKPC−2-mediated carbapenem resistance in Escherichia coli by CRISPR-Cas9 system
Tao, S., Chen, H., Li, N., Fang, Y., Zhang, H., Yao, X., Chen, L., & Liang, W. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03058-7 · Cited by 35
“The endonuclease Cas9, guided by a sgRNA, recognizes and cleaves double-stranded DNA (dsDNA) and causes double-stranded breaks at the target site near the protospacer adjacent motif (PAM) sequence, followed by non-homologous end joining (NHEJ) or homologous recombination (HR) [14].”
BackgroundAllemailem, K. S., Almatroudi, A., Alrumaihi, F., Alradhi, A. E., Theyab, A., Algahtani, M., Alhawas, M., Dobie, G., Moawad, A. A., Rahmani, A. H., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479068 · Cited by 33
“86 It triggers non-specific ssDNA cleavage by utilizing the His-Asp (HD) domain of Csm1 or Cmr2 (also known as Cas10).”
MethodCRISPR–Cas based platforms for RNA detection: fundamentals and applications
Bagi, M., Jamalzadegan, S., Steksova, A., & Wei, Q. (2025) · Chemical Communications · doi:10.1039/d5cc03257a · Cited by 31
RNA-Dependent RNA Targeting by CRISPR-Cas Systems: Characterizations and Applications
Gunitseva, N. M., Evteeva, M. A., Borisova, A., Patrushev, M. V., & Subach, F. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086894 · Cited by 32
“Additionally, it was shown that RNA binding was crRNA- and tracrRNA-dependent, and that target RNA cleavage required the CjeCas9 HNH domain [87].”
BackgroundSaifullah, S., Sakari, M., Suzuki, T., Yano, S., & Tsukahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238904 · Cited by 29
Potential Use of CRISPR/Cas13 Machinery in Understanding Virus–Host Interaction
Bayoumi, M. M., & Munir, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.743580 · Cited by 30
“The CRISPR–Cas systems have been identified in some bacterial lineages and archaea (Van Der Oost et al., 2014; Burstein et al., 2016; Burmistrz et al., 2020).”
BackgroundChoudhary, N., Tandi, D., Verma, R. K., Yadav, V. K., Dhingra, N., Ghosh, T., Choudhary, M., Gaur, R. K., Abdellattif, M. H., Gacem, A., et al. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1164461 · Cited by 27
CRISPR-Cas13 technology portfolio and alliance with other genetic tools
Wu, S., Tian, P., & Tan, T. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.108047 · Cited by 26
Sharma, K. K., Palakolanu, S. R., Bhattacharya, J., Shankhapal, A. R., & Bhatnagar-Mathur, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999207 · Cited by 24
“Among all Cas proteins, the type VI system has relatively simple and exclusive targets for RNA editing (Abudayyeh et al., 2017; Cox et al., 2017; Yan et al., 2018; Burmistrz et al., 2020).”
BackgroundUnity among the diverse RNA-guided CRISPR-Cas interference mechanisms
Ganguly, C., Rostami, S., Long, K., Aribam, S. D., & Rajan, R. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107295 · Cited by 25
Pathogenesis and Treatment of Usher Syndrome Type IIA
Zaw, K., Carvalho, L. S., Aung-Htut, M. T., Fletcher, S., Wilton, S. D., Chen, F. K., & McLenachan, S. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000546 · Cited by 25
Rostoks, N. (2021) · Agronomy · doi:10.3390/agronomy11030572 · Cited by 25
Sridhara, S., Rai, J., Whyms, C., Goswami, H. N., He, H., Woodside, W. T., Terns, M. P., & Li, H. (2022) · Communications Biology · doi:10.1038/s42003-022-03187-1 · Cited by 22
Boti, M. A., Diamantopoulos, M. A., & Scorilas, A. (2025) · Genes · doi:10.3390/genes16101168 · Cited by 23
“More recent innovations include CRISPR-Cas13 systems, which enable programmable RNA cleavage and editing, offering high specificity and modularity for both research and therapeutic applications [41,50].”
Mechanistic insights into the versatile class II CRISPR toolbox
Zhang, F., & Huang, Z. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.11.007 · Cited by 22
Proximity labeling reveals a new in vivo network of interactors for the histone demethylase KDM5
Yheskel, M., Sidoli, S., & Secombe, J. (2023) · Epigenetics & Chromatin · doi:10.1186/s13072-023-00481-y · Cited by 20
Song, Y., Shi, J., Wu, Y., Huang, K., & Tan, X. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134821 · Cited by 18
Advances in breast cancer research using CRISPR/Cas9 system
Eskandari, F., Aali, M., Hadisadegh, S. N., & Azadeh, M. (2024) · Nano Select · doi:10.1002/nano.202400015 · Cited by 20
Recent advances in CRISPR technologies for genome editing
Song, M., & Koo, T. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01336-4 · Cited by 18
Application of CRISPR-Based Biosensors in Analytical Chemistry
Zhou, X., Liu, J., You, J., Shi, M., & Yin, L. (2025) · Journal of Analysis and Testing · doi:10.1007/s41664-025-00398-3 · Cited by 21
Genome editing and its role in vaccine, diagnosis, and therapeutic advancement
Bisht, D., Salave, S., Desai, N., Gogoi, P., Rana, D., Biswal, P., Sarma, G., Benival, D. M., Kommineni, N., & Desai, D. N. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131802 · Cited by 17
Aloliqi, A. A., Alnuqaydan, A. M., Albutti, A., Alharbi, B. F., Rahmani, A. H., & Khan, A. A. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5531 · Cited by 20
“…research following the identification of t r a n s c r i p ti on v e r s a tilit y a nd h i gh t h r oughpu t c h a ll e ng e s a nd d a t a i n t e r p r e t a ti on a nd t a r g e t s it e r e po r t e r s RNA‑programmable nucleases from the prokaryotic adap‑ tive immune system (192,193).”
Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
Chan, K., Ang, G. Y., Yu, C. Y., & Yean, C. Y. (2021) · Life · doi:10.3390/life11111210 · Cited by 15
“widespread adoption as a toolkit for CRISPR-based applications that range from RNA knockdown, editing, imaging, and tracking to nucleic acid detection and regulation of gene expression [26].”
BackgroundMaking the Next Generation of Therapeutics: mRNA Meets Synthetic Biology
Hınçer, A., Ahan, R. E., Aras, E., & Şeker, U. Ö. Ş. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00253 · Cited by 16
Artificial RNA Editing with ADAR for Gene Therapy
Bhakta, S., & Tsukahara, T. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200516170137 · Cited by 17
CRISPR use in diagnosis and therapy for COVID-19
Deol, P., Madhwal, A., Sharma, G., Kaushik, R. K., & Malik, Y. S. (2022) · Methods in microbiology · doi:10.1016/bs.mim.2022.03.002 · Cited by 16
Siva, N., Gupta, S., Gupta, A., Shukla, J. N., Malik, B., & Shukla, N. (2021) · 3 Biotech · doi:10.1007/s13205-021-02680-4 · Cited by 17
Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13
Burris, B. J. D., Molina Vargas, A. M., Park, B. J., & O'Connell, M. R. (2022) · Methods · doi:10.1016/j.ymeth.2022.08.007 · Cited by 13
Jamehdor, S., Pajouhanfar, S., Saba, S., Uzan, G., Teimoori, A., & Naserian, S. (2022) · Cells · doi:10.3390/cells11060999 · Cited by 13
CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges
Shademan, B., Masjedi, S., Karamad, V., Isazadeh, A., Söğütlü, F., rad, M. H. S., & Nourazarian, A. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10193-9 · Cited by 13
COVID-19 mitigation: nanotechnological intervention, perspective, and future scope
Adhikari, A., Mandal, D., Rana, D. K., Nath, J., Bose, A., Sonika, S., Orasugh, J. T., De, S., & Chattopadhyay, D. (2023) · Materials Advances · doi:10.1039/d2ma00797e · Cited by 12
The use of CRISPR-Cas-based systems in bacterial cell factories
Kolasinliler, G., Aagre, M. M., Akkale, C., & Kaya, H. B. (2023) · Biochemical Engineering Journal · doi:10.1016/j.bej.2023.108880 · Cited by 12
Research progress of CRISPR/Cas systems in nucleic acid detection of infectious diseases
Dong, J., Du, Y., & Zhou, L. (2023) · iLABMED · doi:10.1002/ila2.6 · Cited by 11
Genomic attributes of airway commensal bacteria and mucosa
Cuthbertson, L., Löber, U., Ish-Horowicz, J., McBrien, C., Churchward, C. P., Parker, J. C., Olanipekun, M. T., Burke, C. M., McGowan, A., Davies, G. A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05840-3 · Cited by 14
“Type III RNA-targeting system elements (such as cas10 , cas7 , csm2 and csm5 ) 51 are present in our isolates (particularly Fusobacteria and Pre-votella spp.), as is the Type II system element cas9 (Supplementary Data 4).”
BackgroundEpitranscriptomic signatures in stem cell differentiation to the neuronal lineage
Șelaru, A., Costache, M., & Dinescu, S. (2021) · RNA Biology · doi:10.1080/15476286.2021.1985348 · Cited by 11
“system, which can target a specific nucleic acid site within RNA molecules [107].”
BackgroundCRISPR/Cas-mediated genome editing for improved stress tolerance in plants
Pandita, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90943-3.00001-8 · Cited by 13
Setia, A., Patil, D., Randhave, N. V., Vaishali, Verma, N., Rani, K., Kale, A., Wagh, B., Kumar, V., Malik, A. K., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150582 · Cited by 9
Robust genome and RNA editing via CRISPR nucleases in PiggyBac systems
Jiang, Y., Hoenisch, R. C., Chang, Y., Bao, X., Cameron, C. E., & Lian, X. L. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.046 · Cited by 12
The Trend of CRISPR-Based Technologies in COVID-19 Disease: Beyond Genome Editing
Yousefi-Najafabadi, Z., Fanuel, S., Falak, R., Kaboli, S., & Kardar, G. A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-021-00431-7 · Cited by 8
Flavivirus–Host Interaction Landscape Visualized through Genome-Wide CRISPR Screens
Kanojia, A., Sharma, M., Shiraz, R., & Tripathi, S. (2022) · Viruses · doi:10.3390/v14102164 · Cited by 12
Soltani, S., Fallah, T., Shafiei, M., Shahraki, A. H., & Iranbakhsh, A. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.04.022 · Cited by 8
Advances in CRISPR-Cas systems for epigenetics
Ilyas, M., Shah, Q., Gul, A., Ibrahim, H., Fatima, R., Babar, M. M., & Rajadas, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.003 · Cited by 10
Gong, L., Liu, X., Wu, J., & He, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01292-x · Cited by 11
“Recent development of RCas-based systems provided alternative routes for RNA knockdown through site-specific RNA cleavage or indiscriminate RNA degradation [50, 51], with potentially higher efficiency and specificity than traditional RNAi.”
BackgroundCOVID-19: CRISPR/Cas-like System of nsp3 Promotes the Mutant Recombination and Drug ResistancePreprint
Liu, W., & hualan, L. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14394284.v1 · Cited by 8
Characterization of Limnospira platensis PCC 9108 R-M and CRISPR-Cas systems
Castillo, M., Guevara, G., Baldanta, S., Rodríguez, P. S., Agudo, L., Nogales, J., Carrasco, A. D., Arribas-Aguilar, F., Pérez-Pérez, J., García, J. L., et al. (2024) · Microbiological Research · doi:10.1016/j.micres.2023.127572 · Cited by 7
Liu, Y., Jia, S., Wu, Y., Zhou, N., Xie, Y., Wei, R., Huang, Z., Chen, Y., Hu, F., & Zheng, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116706 · Cited by 8
Improvement of floricultural traits in ornamental crops using genome editing tools
Jadhav, P. R., Aglawe, S. B., Harish, D. K., Wagh, Y. S., Barbadikar, K. M., Kumar, P. N., Kawar, P. G., Prasad, K. V., & Kumar, S. P. J. (2023) · Journal of Plant Biochemistry and Biotechnology · doi:10.1007/s13562-023-00851-3 · Cited by 7
“There are good reviews available on RNA-Targeting CRISPR–Cas systems and their potential applications in various fields (Wang et al. 2019; Burmistrz et al. 2020; Smargon et al. 2020).”
Diversity of Bathyarchaeia viruses in metagenomes and virus-encoded CRISPR system components
Duan, C., Liu, Y., Liu, Y., Liu, L., Cai, M., Zhang, R., Zeng, Q., Koonin, E. V., Krupovic, M., & Li, M. (2024) · ISME Communications · doi:10.1093/ismeco/ycad011 · Cited by 7
“These Acrs function by directly interacting with various components of the CRISPR-Cas system [27-29] or modulating the levels of cyclic oligoadenylate [30], thereby suppressing the functionality of the CRISPR-Cas system.”
BackgroundKaul, T., Sony, S. K., Bharti, J., Motelb, K. F. A., Verma, R., Thangaraj, A., Kaul, R., Nehra, M., & Eswaran, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-1445-4_9 · Cited by 8
Challenges and Opportunities Used in RNA-Based Therapeutics
Chauhan, P., Tiwari, I., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_10 · Cited by 6
Yu, X., He, Q., & Kong, Q. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1387623 · Cited by 7
The CRISPR Patent Landscape: Focus on Chinese Researchers
Bire, S., Jordan, C. L. B., & Palazzoli, F. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.0020 · Cited by 5
“29,30 Consequently, a decrease in the number of patent families covering genome-editing applications can be observed with concomitant with a rise in the transcriptional-epigenetic regulation and other application categories (Fig.”
Not making the cut: Techniques to prevent RNA cleavage in structural studies of RNase–RNA complexes
Jones, S., Goossen, C., Lewis, S. D., Delaney, A. M., & Gleghorn, M. L. (2022) · Journal of Structural Biology X · doi:10.1016/j.yjsbx.2022.100066 · Cited by 8
CRISPR/Cas-based biosensors: applications for early diagnosis of cardiovascular disease
Bahaabadi, Z. J., Kesharwani, P., Karav, S., & Sahebkar, A. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117609 · Cited by 4
CRISPR/Cas Systems for Enhancing Photosynthesis: Climate Resilience and Food Production
Barupal, M., & Kumar, A. (2024) · Springer eBooks · doi:10.1007/978-981-99-8529-6_18 · Cited by 8
Unlocking the Power of Molecular Cloning: Revolutionizing Medical Microbiology Procedures
Datta, N. (2024) · University of Michigan Undergraduate Research Journal · doi:10.3998/umurj.5509 · Cited by 5
COVID-19 diagnosis—myths and protocols
Muzammil, I., Aqib, A. I., Tanveer, Q., Muzmmal, S., Naseer, M. A., & Tahir, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90769-9.00027-x · Cited by 4
Idakwoji, P. A., Fadipe, D. E., Aliyu, A. O., Mobolanle, B. F., Nwafor, I. P., Isiah, Z., Muhammed, S. I., Hussaini, M., Muhammed, H., Imam, H. S., et al. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100420 · Cited by 3
Vraggalas, S., Oussama, G., Shalha, B., Bazakos, C., Robert, H. S., Lakhneko, O., & Fragkostefanakis, S. (2025) · Physiologia Plantarum · doi:10.1111/ppl.70639 · Cited by 3
CRISPR-based tools in food safety and microbiology: applications for pathogen detection and control
Azhar, F., Mazhari, B. B. Z., Ibrahim, M. N., Alanazi, A., & Islam, F. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04919-1 · Cited by 2
“Although this property is a derivation of bacterial immune response to RNA phages, it has been adapted tactically to food microbiology as a high-sensitivity method of detection of RNA viruses and transcriptional signatures of foodborne pathogens (Burmistrz et al. 2020).”
CRISPR-Cas and Nanotech in Aquaculture: Pioneering Genetic Advancements for Food Security
Ghara, S., Biswas, S., Patel, R. S., Rather, M. A., & Ahmad, I. (2025) · Springer eBooks · doi:10.1007/978-3-031-92858-1_14 · Cited by 2
Online Databases of Genome Editing in Cardiovascular and Metabolic Diseases
Carrillo-Rodríguez, P., Martínez‐López, J., Gómez-Hernández, L., Boraita-Morales, L., Uceda-Molina, M., Cuenca-Bermejo, I., Valencia-Aguirre, J. P., Mora-López, M., & Plaza‐Díaz, J. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_2 · Cited by 1
Alam, A., Abbas, S., Hussain, H., Mehar, I., Ahmad, B., Khan, K. A., Ghramh, H. A., Ali, J., & Chen, R. (2025) · International Journal of Tropical Insect Science · doi:10.1007/s42690-025-01668-4 · Cited by 1
“However, there are different Cas13 proteins such as C2c2 known as Cas13a, C2c6 known as Cas13b, C2c7 known as Cas13c, and proto-spacer flanking sequence (PFS)–independent Cas13d (Burmistrz et al. 2020 ).”
Gençoğlu, H. S., Aydemir, E., & Ayaz, F. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02373-z · Cited by 1
“In some subtypes of Type I systems, the immune response occurs through an abortive mechanism involving the death of the infected cell; this strategy is known as a defense model that provides benefits at the community level (Burmistrz et al. 2020; Watson et al. 2019).”
Ba Cas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA
Li, X., Wu, C., Guo, J., Zheng, R., Kong, J., Du, L., She, Q., & Ji, S. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag915 · Cited by 1
“CRISPR–Cas12a2, along with Type III and Type VI systems, is characterized by an RNA-targeting immune response [ 20 , 23 , 64 , 65 ].”
Metadata
- Authors
- Burmistrz, M., Krakowski, K., & Krawczyk-Balska, A.
- Affiliations
- Department of Molecular Microbiology, Biological and Chemical Research Centre, Faculty of Biology, University of Warsaw, 02-089 Warsaw, Poland
- University of Warsaw (PL)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-07
- Volume
- 21
- Issue
- 3
- Pages
- 1122
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7036953
- OpenAlex
- W3004935084
- Cited by
- 125
- References
- 81
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 18 · 2023: 21 · 2022: 30 · 2021: 24 · 2020: 8
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Center of Science, Poland (2016/21/B/NZ6/00963)
- Ministry of Science and Higher Education through the Faculty of Biology, University of Warsaw (intramural grant DSM no. 501-D114-01-1140400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- CRISPR/Cas9, Cas13, type III CRISPR-Cas, RNA interference, RNA cleavage, genome editing tools
- MeSH terms
- Gene Editing, Animals, Humans, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.